Abstract:gation of cognitive decline, specifically, testing all particular cognitive domains rather than the extreme of dementia. Steenland’s article concludes that elderly adults with normal cognition at baseline who used statins had a slower rate of annual worsening on the Clinical Dementia Rating Scale Sum of Boxes (CDR-SOB) than nonusers. Arguably, this research illustrates that the rate of decline in subtle cognitive domains may be clinically relevant in monitoring statin response. The authors studied individuals with an average age of 73, the majority of whom were white women, although community-dwelling older adults have various ethnic backgrounds, especially in urban settings. The authors argue that the subjects were matched for underlying conditions, but it would be important to note what other comorbid conditions existed (e.g., chronic obstructive pulmonary disease, congestive heart failure, myocardial infarction, baseline lipid profiles, ratios of highto low-density lipoprotein cholesterol to correlate dyslipidemia status in the two cohorts, how the authors defined heart disease, and whether participants were taking aspirin or other antiplatelet medications that could have confounded the results). The article did not mention about loss to follow-up and possible explanations for such. It also did not discuss any additional reasons for new cognitive impairment throughout the study (e.g., development of stroke). As emerging evidence connects functional decline with early cognitive decline, it would be helpful to have the mean or median baseline CDR-SOB score available in Table 1 to help readers appreciate the changes mentioned in Table 2. Given the unreliable nature of self-reported information, the question arises as to how the authors verified that the subjects were taking their statins. Were these “professional patients,” who would be much more cognitively and physically independent than the average older adult? If so, could the proposed relationship be generalized to the older population as a whole? A noteworthy problem is the presence of recall bias as a potential threat to internal validity given that the outcome of the study is a measure of cognitive decline, which in itself could contribute to recall bias. The spread between different statin medications appears to be consistent with the general participant population. Discussion regarding lipophilicity of different statins would have been of interest, because statins that are lipophilic are thought to provide more of a benefit in Alzheimer’s disease. Additionally, a vital question is left unanswered—how long have individuals in the subset been treated with statins, and what is the anticipated time to benefit? Given the small degree of correlation between cognitive decline and statin use, a concern arises over underlying confounders that may account for the outcomes seen in statin users who had normal cognition at baseline. Rather than highlight an association, the article could have elaborated on the clinical significance, or lack thereof, of the small relational differences between the two cognitive groups. The short follow-up of 2.8 and 3.4 years, respectively, may reflect an insufficient time to detect major differences. Future research should be aimed at establishing a long-term correlation between statin use and cognitive decline, with potential implications for clinical practice.

Evidence for benefit of statins to modify cognitive decline and risk in Alzheimer's disease

Does taking statins affect the pathological burden in autopsy-confirmed Alzheimer's dementia?

Response to Buslovich and Colleagues

Overview the effect of statin therapy on dementia risk, cognitive changes and its pathologic change: a systematic review and meta-analysis.

Statins Are Linked to Reduced Alzheimer’s Risk, Study Finds

Cognitive function in dyslipidemia patients: exploring the impact of statins

Selected LDLR and APOE Polymorphisms Affect Cognitive and Functional Response to Lipophilic Statins in Alzheimer's Disease

Hypercholesterolemia and Alzheimer's Disease: Unraveling the Connection and Assessing the Efficacy of Lipid-Lowering Therapies

Influence of statin potency and liposolubility on Alzheimer's disease patients: A population-based study

Statins and cognitive decline in older adults with normal cognition or mild cognitive impairment.

Association of blood lipids, atherosclerosis and statin use with dementia and cognitive impairment after stroke: A systematic review and meta-analysis

Do Statins Affect Cognitive Health? A Narrative Review and Critical Analysis of the Evidence

STAREE-Mind Imaging Study: a randomised placebo-controlled trial of atorvastatin for prevention of cerebrovascular decline and neurodegeneration in older individuals

Statin Use is Associated with Lower Risk of Dementia in Stroke Patients: a Community-Based Cohort Study with Inverse Probability Weighted Marginal Structural Model Analysis

Effects of Simvastatin on Plasma Amyloid-β Transport in Patients with Hyperlipidemia: A 12-Week Randomized, Double-Blind, Placebo-Controlled Trial.

Evaluation of High Cholesterol and Risk of Dementia and Cognitive Decline in Older Adults Using Individual Patient Meta-Analysis.

Statin Use and All-Cause Mortality in Nursing Home Residents With and Without Dementia

Role of endolysosomes and cholesterol in the pathogenesis of Alzheimer's disease: Insights into why statins might not provide clinical benefit

Association Between Statin Use and Dementia, and Related Mechanisms: A Bibliometric Analysis from 2007 to 2023

Simvastatin improves learning and memory impairment via gut-brain axis regulation in an ovariectomized/D-galactose Alzheimer's rat model

Adverse effects of statin therapy: perception vs. the evidence – focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract